• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 6:03:37 AM ET
    $ITMR
    Medical/Dental Instruments
    Health Care
    Get the next $ITMR alert in real time by email
    SC 13G/A 1 tm216813-1_sc13ga.htm SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549  

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

     

    Under the Securities Exchange Act of 1934

     

    ITAMAR MEDICAL LTD.
    (Name of Issuer)
     
    Ordinary Shares, par value NIS 0.01 per share
    (Title of Class of Securities)
     
      465437101  
    (CUSIP Number)
     
    December 31, 2020
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

     

    ¨ Rule 13d-1(c)

     

    x Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     Page 1 of 4 pages 

     

     

    CUSIP NO. 465437101  

     

     

    1. Name of Reporting Persons/
    I.R.S. Identification Nos. of above persons (entities only).
    Giora Yaron
    2. Check the Appropriate Box if a Member of a Group
      (a) ¨
      (b) ¨
    3. SEC Use only  

    4. Place of Organization Israel

    Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power 30,639,185*
    6. Shared Voting Power 0
    7. Sole Dispositive Power 30,639,185*
    8. Shared Dispositive Power 0

    9. Aggregate Amount Beneficially Owned by Each Reporting Person 30,639,185*
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares  
    11. Percent of Class Represented by Amount in Row (9) 6.2%**
    12. Type of Reporting Person :   IN

      

    * Consists of  (a) 29,845,759 Ordinary Shares, (b) 9,237 ADSs, representing 277,110 Ordinary Shares and (c) 516,316 Ordinary Shares issuable upon exercise of options to purchase Ordinary Shares that are exercisable within 60 days that are held by the Reporting Person directly and through a company wholly-owned by the Reporting Person and his wife.

    ** Based on information received from the Issuer, there were 491,430,074 shares of Ordinary Shares (including Ordinary Shares represented by ADSs) outstanding as of February 10, 2021 and 516,316 Ordinary Shares issuable upon the exercise of options to purchase Ordinary Shares held by the Reporting Person that are exercisable within 60 days.

     

     Page 2 of 4 pages 

     

     

    Item 1.

     

    (a)Name of Issuer: Itamar Medical Ltd. (the “Issuer”).

     

    (b)Address of Issuer’s Principal Executive Offices:
    9 Halamish Street, Caesarea 3088900, Israel

     

    Item 2.

     

    (a)Name of Person Filing:

    This Statement is filed by:

     

    Giora Yaron

     

    The foregoing is referred to as the “Reporting Person” in this Statement.

     

    (b)Address of Principal Business Offices or, if none, Residence:

     

    Giora Yaron – c/o Itamar Medical Ltd., 9 Halamish Street, Caesarea 3088900, Israel

     

    (c)Citizenship or Place of Organization:

    Israel.

     

    (d)Title of Class of Securities:

    Ordinary Shares, par value NIS 0.01 per share (the “Ordinary Shares”).

     

    (e)CUSIP Number:

    465437101. The CUSIP Number relates to American Depositary Shares, each of which represents thirty (30) Ordinary Shares (the “ADSs”).

     

    Item 3.If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
    Not applicable.

     

    Item 4.Ownership

    See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person.

     

    Item 5.Ownership of 5 Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ].

     

    Item 6.Ownership of More than 5 Percent on Behalf of Another Person
    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person
    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group
    Not applicable.

     

    Item 9.Notice of Dissolution of Group
    Not applicable.

     

    Item 10.Certifications

    Not applicable.

     

     Page 3 of 4 pages 

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    February 16, 2021

     

     

    Giora Yaron

     

    /s/ Giora Yaron

     

     Page 4 of 4 pages 

     

    Get the next $ITMR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ITMR

    DatePrice TargetRatingAnalyst
    9/20/2021$30.00 → $31.00Outperform → Market Perform
    SVB Leerink
    9/15/2021$33.85Buy → Neutral
    Ladenburg Thalmann
    9/14/2021$36.00 → $31.00Buy → Neutral
    HC Wainwright & Co.
    9/14/2021$30.00 → $31.00Outperform → Market Perform
    Cowen & Co.
    More analyst ratings

    $ITMR
    Leadership Updates

    Live Leadership Updates

    See more
    • Itamar Medical Appoints Marga Ortigas-Wedekind to its Board of Directors

      CAESAREA, Israel, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the appointment of Marga Ortigas-Wedekind to its Board of Directors. Ms. Ortigas-Wedekind brings more than 30 years of medical technology and digital health experience including leadership roles in commercial and strategic marketing. She is currently the Chief Commercial Strategy Officer for Fogarty Innovation, a nonprofit organization in the medical technology space. In this role she is responsible for delivering commercial strategy gu

      8/12/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical Appoints Brad Fluegel to its Board of Directors

      CAESAREA, Israel, May 24, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the appointment of Brad Fluegel to its Board of Directors. Mr. Fluegel's vast experience includes wide ranging leadership roles and 25+ years in the healthcare sector, primarily in strategy and business development. Most recently, Mr. Fluegel was Senior Vice President, Chief Healthcare Commercial Market Development Officer for Walgreens Co. In this role he was responsible for driving all commercial healthcare activities, including sales

      5/24/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care

    $ITMR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Itamar Medical Reports Third Quarter 2021 Financial Results

      - Revenues Increased 23% Year-over-Year to $13.6 Million - - U.S. WatchPAT™ Revenues Increased 27% Year-over-Year to $11.3 Million - CAESAREA, Israel, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today reported unaudited financial results for the third quarter of 2021. "Third quarter results represent the strong traction our WatchPAT™ platform technology has gained entering the second half of 2021. Growth in the U.S. continues to outpace our overall growth on top of expanding adoption in the markets we serve thr

      11/18/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical Appoints Marga Ortigas-Wedekind to its Board of Directors

      CAESAREA, Israel, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the appointment of Marga Ortigas-Wedekind to its Board of Directors. Ms. Ortigas-Wedekind brings more than 30 years of medical technology and digital health experience including leadership roles in commercial and strategic marketing. She is currently the Chief Commercial Strategy Officer for Fogarty Innovation, a nonprofit organization in the medical technology space. In this role she is responsible for delivering commercial strategy gu

      8/12/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical Reports Second Quarter 2021 Financial Results

      - Revenues Increased 41% Year-over-Year to $12.6 Million - - U.S. WatchPATTM Revenues Increased 53% Year-over-Year to $10.1 Million - - Raised Full Year 2021 Revenue Guidance to a Range of $53 Million to $54 Million - - Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT - CAESAREA, Israel, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today reported unaudited financial results for the second quarter of 2021. "Our second quarter results demonstrated further growth as our WatchPAT™ technol

      8/10/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care

    $ITMR
    Financials

    Live finance-specific insights

    See more
    • Itamar Medical Reports Third Quarter 2021 Financial Results

      - Revenues Increased 23% Year-over-Year to $13.6 Million - - U.S. WatchPAT™ Revenues Increased 27% Year-over-Year to $11.3 Million - CAESAREA, Israel, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today reported unaudited financial results for the third quarter of 2021. "Third quarter results represent the strong traction our WatchPAT™ platform technology has gained entering the second half of 2021. Growth in the U.S. continues to outpace our overall growth on top of expanding adoption in the markets we serve thr

      11/18/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical Reports Second Quarter 2021 Financial Results

      - Revenues Increased 41% Year-over-Year to $12.6 Million - - U.S. WatchPATTM Revenues Increased 53% Year-over-Year to $10.1 Million - - Raised Full Year 2021 Revenue Guidance to a Range of $53 Million to $54 Million - - Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT - CAESAREA, Israel, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today reported unaudited financial results for the second quarter of 2021. "Our second quarter results demonstrated further growth as our WatchPAT™ technol

      8/10/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical to Report Second Quarter Financial Results and Host Conference Call on Tuesday, August 10, 2021

      CAESAREA, Israel, July 28, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, announced today that it will report its financial results for the second quarter 2021 before the U.S. market opens on Tuesday, August 10, 2021. The Company will host a conference call that day at 8:00 a.m. Eastern Time, 3:00 p.m. Israel Time to review financial results and provide a corporate update. The call will be hosted by Gilad Glick, President and CEO, and Shy Basson, CFO. To listen live via webcast, please visit https://edge.media-server.com/mm

      7/28/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care

    $ITMR
    SEC Filings

    See more
    • SEC Form 15-12B filed by Itamar Medical Ltd.

      15-12B - Itamar Medical Ltd. (0001613170) (Filer)

      12/27/21 6:02:01 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Itamar Medical Ltd.

      EFFECT - Itamar Medical Ltd. (0001613170) (Filer)

      12/27/21 12:15:19 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Itamar Medical Ltd.

      EFFECT - Itamar Medical Ltd. (0001613170) (Filer)

      12/27/21 12:15:09 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care

    $ITMR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Itamar Medical Ltd. (Amendment)

      SC 13G/A - Itamar Medical Ltd. (0001613170) (Subject)

      10/4/21 6:02:57 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Itamar Medical Ltd. (Amendment)

      SC 13G/A - Itamar Medical Ltd. (0001613170) (Subject)

      6/17/21 11:07:03 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Itamar Medical Ltd. (0001613170) (Subject)

      2/16/21 6:35:46 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care

    $ITMR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Itamar Medical downgraded by SVB Leerink with a new price target

      SVB Leerink downgraded Itamar Medical from Outperform to Market Perform and set a new price target of $31.00 from $30.00 previously

      9/20/21 6:33:53 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical downgraded by Ladenburg Thalmann with a new price target

      Ladenburg Thalmann downgraded Itamar Medical from Buy to Neutral and set a new price target of $33.85

      9/15/21 7:36:23 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical downgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. downgraded Itamar Medical from Buy to Neutral and set a new price target of $31.00 from $36.00 previously

      9/14/21 6:31:39 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care